1Y Annualised Return
▼-35.59%
3Y Annualised Return
▲12.31%
5Y Annualised Return
▲4.02%
10Y Annualised Return
▲12.11%
Alembic Stock Performance
|
|
|
Alembic Company background
Founded in: 1907
Managing director: Malika C Amin
Alembic Limited is one of the Indias most experienced manufactures of bulk drugs and pharmaceuticals formulation in human and animal healthcare. The Company operates primarily in the manufacture of Bulk Drugs and Real Estate Business. The company manufacture pharmaceuticals and chemicals, bulk drugs (penicillin and other antibiotics) and formulations. It works manufacturing facilities at Vadodara in Gujarat and Solan in Himachal Pradesh.Alembic Limited was incorporated in year 1907 with the name Alembic Chemical Works Company Limited in Vadodara to manufacture tinctures and alcohol. The name of the Company was changed to Alembic Limited in August, 1999. The Company started to manufacture cough syrup, vitamins, tonics and sulphur durgs in 1940. In 1961, it inaugurated the Pencillin Palnt. In 1968, it started to manufacture Streptomycin.In the 1971, they manufactured Erythromycin using expertise from Eli Lilly, USA and in the year 1972, they launched Althrocin, a brand of Erythromycin. In year 1997, Althrocin become top selling brand in India. In the year 2001, they started to manufacture Cephalosporin C. In June 2001, the company formed a wholly owned subsidiary company named Alembic Europe Pvt Ltd in UK.In the year 2005, the company has launched ZERO, a new generation, no calories, Sucralose Based Sugar Substitute which gave entry for the company into the highgrowth lifestyle OTC product segment. In May 2005, the generic alliances and API division were merged to form an independent SBU.The company has set up a formulation manufacturing facility at Baddi in Himachal Pradesh with a production capacity 900 million tablets and 600 million liquid oral bottles annually. During the year 200506, the company has increased the installed capacity of Tablets Capsules and Oral Preparation Ointments by 595 Million Nos and 720 MT respectively.During the year 200506, the company acquired API Plant at Karakhadi in Vadodara. In the year 2007, the company acquired the NonOncology Business of Dabur Pharma Ltd. Also in the same year, they entered into a licensing agreement for its Novel Drug Delivery Platform for Keppra XR with UCB Belgium. During the year 200708, the company acquired the API manufacturing facility of Nirayu Pvt Ltd at Panelav near Vododara.The Company formed a wholly owned subsidiary viz. Alembic Global Holding SA in Neuchatel, Switzerland in 2009. The Pharmaceutical Undertaking of the Company demerged and the same got transferred to Alembic Pharmaceuticals Limited with effect from Appointed date i.e. 1st April, 2010. The maiden real estate project Samsara was completed in 2014. The Company launched second real estate project, VEDA in 201516. It further launched two APIs in 2017. During year 201718, Alembic City Limited (formerly known as Alembic Exports Limited) became whollyowned subsidiary of the Company.During 201819, the Composite Scheme of Arrangement comprising of transfer and vesting of the Identified Real Estate Undertaking of Alembic Limited (the Company / the First Demerged Company) into Shreno Limited (the First Transferee Company/ the Second Demerged Company) and transfer and vesting of Engineering Division and Investment Division of Shreno Limited into Nirayu Private Limited (the Second Transferee Company) and their respective shareholders with effect from the Appointed Date i.e. 1st November, 2018 was sanctioned by the Honble National Company Law Tribunal, Ahmedabad Bench (NCLT) vide its order dated 26th July, 2019. Accordingly, Scheme was made effective from 26th July, 2019.The Company launched a residential project VEDA II during 2020. In FY 2025, VEDAII, one of the Companys gated community project has been completed in FY 2025. The Companys upscale premium residential projects, Townhouse24 also achieved 100% sales during the year. Other premium projects like The Villas and The Gardens witnessed decent demand. The Company also launched another housing project with 3BHK and 4BHK configurations called The Park Crescent.
Alembic Financial Highlights
Alembic reported a Q2 FY 2025-26
revenue of ₹55.86 crore,
up 39.8% YoY,
with net profit increased
55.7% to ₹76.06 crore. For the full year FY2025–2026, revenue
reached ₹296.78 crore and profit touched at
₹144.57 crore.
Alembic Share Price Today
As of 7 Dec 2025, Alembic share price is ₹100.8. The stock opened at ₹102.8 and had closed at ₹102.7 the previous day. During today’s trading session, Alembic share price moved between ₹100.25 and ₹102.81, with an average price for the day of ₹101.53. Over the last 52 weeks, the stock has recorded a low of ₹85.46 and a high of ₹153.39. In terms of performance, Alembic share price has declined by 10% over the past six months and has declined by 35.59% over the last year.
Alembic SIP Return Calculator
Over the past
1 year
3 years
5 years
Total Investment of ₹3,00,000
Monthly SIP of ₹5,000 would have become ₹3,32,773 in 5 years with a gain of ₹32,773 (+10.92%)
Alembic Fundamental
Market Cap (in crs)
2,589.64
Face Value
2
Turnover (in lacs)
250.18
Key Metrics
Qtr Change %
34.25% Fall from 52W High
-3.3
Dividend yield 1yr %
High in industry
2.4
Alembic Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Alembic Quarterly Revenue
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
55.86 Cr | 49.75 Cr | 60.27 Cr | 57.92 Cr | 52.91 Cr |
Alembic Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
296.78 Cr | 212.26 Cr | 191.51 Cr | 167.4 Cr | 83.79 Cr | 167.33 Cr |
Alembic Quarterly Net Profit/Loss
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
76.06 Cr | 17.81 Cr | 23.75 Cr | 26.09 Cr | 77.31 Cr |
Alembic Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
144.57 Cr | 92.87 Cr | 80.62 Cr | 86.19 Cr | 13.84 Cr | 93.03 Cr |
Alembic Result Highlights
Result Summary
-
Alembic Ltd reported a 126.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1.9%.
-
Its expenses for the quarter were up by 7.3% QoQ and down 1.9% YoY.
-
The net profit increased 108.4% QoQ and increased 6.2% YoY.
-
The earnings per share (EPS) of Alembic Ltd stood at 5 during Q2 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Alembic Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
100.85
Current Price
Day EMA5
101.40
Day EMA10
100.90
Day EMA12
100.80
Day EMA20
100.60
Day EMA26
100.60
Day EMA50
101.40
Day EMA100
103.70
Day EMA200
107.20
Day SMA5
101.70
Day SMA10
100.30
Day SMA20
100.20
Day SMA30
100.20
Day SMA50
100.50
Day SMA100
104.80
Day SMA150
107.20
Day SMA200
105.20
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 114760 Rs | 263390 Rs |
Week Rs | 248035 Rs | 801208 Rs |
Month Rs | 158737 Rs | 381853 Rs |
Resistance & Support
101.30
Pivot
Resistance
First Resistance
102.36
Second Resistance
103.86
Third Resistance
104.92
Support
First Support
99.80
Second support
98.74
Third Support
97.24
Relative Strength Index
51.12
Money Flow Index
64.79
MACD
0.22
MACD Signal
-0.14
Average True Range
2.38
Average Directional Index
14.71
Rate of Change (21)
1.06
Rate of Change (125)
-10.01
Alembic Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
243.14 | 2,997.93 | 218 | 456.75 | 252.89 | 9.07% | 1.17% | -35.11% | -43.36% | -30.23% | 0.33% | 292.05 | 41.70 | 2.50 | |
84.40 | 2,477.37 | 57.5 | 126.66 | 86.85 | -6.26% | -9.04% | -2.66% | 8.68% | 22.89% | 0.95% | 21.35 | 41.70 | 1.42 | |
42.47 | 2,327.16 | 42 | 91.7 | 43.45 | -2.14% | -11.89% | -34.12% | -50.83% | 33.55% | 0.47% | 41.18 | 41.70 | 1.95 | |
317.00 | 2,968.77 | 176.05 | 335 | 322.45 | -0.69% | 12.87% | 27.08% | 22.51% | 271.85% | 0.12% | 36.57 | 41.70 | 3.90 | |
445.55 | 3,136.93 | 444 | 836.4 | 450.00 | -4.62% | -4.72% | -25.24% | -44.50% | 33.14% | 0.00% | 37.48 | 41.70 | 1.30 | |
552.00 | 2,434.55 | 442.8 | 813 | 550.05 | 7.34% | -10.56% | 16.74% | -31.16% | 32.51% | 0.00% | 0.00 | 41.70 | 1.60 |
Alembic Share Price FAQs
What is Share Price of Alembic ?
Alembic share price is ₹100.85 in NSE and ₹100.98 in BSE as on 5/12/2025.
How has Alembic shares performed in the past ?
Alembic share price in the past 1-year return was -26.95. The Alembic share hit a 1-year low of Rs. 85.46 and a 1-year high of Rs. 153.39.
What is the market cap of Alembic ?
The market cap of Alembic is Rs. 2589.64 Cr. as of 5/12/2025.
What is the current P/E ratio of Alembic ?
The PE ratios of Alembic is 18.36 as of 5/12/2025.
What is the current PB ratio of Alembic ?
The PB ratios of Alembic is 1.02 as of 5/12/2025
How to buy Alembic shares?
You can easily buy Alembic shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Alembic ?
The 52-week high and low of Alembic share price is ₹153.39 and ₹85.46 as of 5/12/2025.
What is the EPS of Alembic ?
The earnings per share (EPS) of Alembic stood at 5 during Q2 FY 2025-26.
Please be aware that Alembic stock prices are subject to continuous fluctuations due to various factors.
Invest in Alembic